Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-25-014183
Filing Date
2025-04-16
Accepted
2025-04-16 16:23:08
Documents
19
Period of Report
2025-05-27

Document Format Files

Seq Description Document Type Size
1 DEF 14A ny20043636x1_def14a.htm   iXBRL DEF 14A 704800
6 GRAPHIC logo_onkure.jpg GRAPHIC 30648
7 GRAPHIC sig_nsaccomano.jpg GRAPHIC 8835
8 GRAPHIC ny20043636x1_pc01.jpg GRAPHIC 637415
9 GRAPHIC ny20043636x1_pc02.jpg GRAPHIC 545360
  Complete submission text file 0001140361-25-014183.txt   4268813

Data Files

Seq Description Document Type Size
2 INLINE XBRL TAXONOMY EXTENSION - SCHEMA okur-20250527.xsd EX-101.SCH 3435
3 INLINE XBRL TAXONOMY EXTENSION - DEFINITION LINKBASE okur-20250527_def.xml EX-101.DEF 3110
4 INLINE XBRL TAXONOMY EXTENSION - LABEL LINKBASE okur-20250527_lab.xml EX-101.LAB 2360
5 INLINE XBRL TAXONOMY EXTENSION - PRESENTATION LINKBASE okur-20250527_pre.xml EX-101.PRE 6960
21 EXTRACTED XBRL INSTANCE DOCUMENT ny20043636x1_def14a_htm.xml XML 54081
Mailing Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301
Business Address 6707 WINCHESTER CIRCLE, SUITE 400 BOULDER CO 80301 (720) 307-2892
OnKure Therapeutics, Inc. (Filer) CIK: 0001637715 (see all company filings)

EIN.: 472309515 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40315 | Film No.: 25843085
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)